Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:50:20.249Z.
Calculation as of: 2026-10-06T12:50:20.249Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c6e002aca1a00fdff6499b7d77acdaecc7ea859b41a0df533897df39264525a0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Adagio Medical Holdings, Inc.
Market Cap
$3.13M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Adagio Medical Holdings, Inc. (ADGM) | $3.13M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.44M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.47M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.48M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.59M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.37M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
